Related Experiment Video
Updated: Aug 14, 2026
Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma
Published on: October 14, 2016
The management of paratesticular rhabdomyosarcoma: a single institutional experience with 44 consecutive children
A Ferrari1, M Casanova, M Massimino
1Division of Pediatric Oncology, Istituto Nazionale Tumori, Milano, Italy.
Insights
Localized paratesticular rhabdomyosarcoma has an excellent prognosis in children. Retroperitoneal lymph node dissection is likely unnecessary for localized disease, given accurate imaging and effective chemotherapy.
Area of Science:
- Pediatric Oncology
- Surgical Oncology
- Pediatric Urology
Background:
- Paratesticular rhabdomyosarcoma is a rare childhood malignancy.
- Treatment strategies have evolved over decades.
- Understanding prognostic factors is crucial for optimizing care.
Purpose of the Study:
- To evaluate the outcomes of children treated for paratesticular rhabdomyosarcoma.
- To assess the role of retroperitoneal lymph node dissection in localized disease.
Main Methods:
- Retrospective review of 44 children treated between 1976 and 1996.
- Classification based on Intergroup Rhabdomyosarcoma Study (IRS) staging.
- Analysis of surgical excision, chemotherapy, and radiotherapy protocols.
Main Results:
- Overall 5-year event-free survival was 77%.
- Survival rates varied significantly by IRS group (93% for groups I/II, 62.5% for group III, 37.5% for group IV).
- Median follow-up was 11 years.
Conclusions:
- Localized paratesticular rhabdomyosarcoma demonstrates an excellent prognosis.
- Retroperitoneal lymph node dissection may be unnecessary for localized disease.
- Accurate staging, chemotherapy, and radiotherapy are key treatment components.
Purpose:
We report a single institutional experience with 44 consecutive children treated from 1976 to 1996 for paratesticular rhabdomyosarcoma.
Materials And Methods:
After primary surgical excision, 27 cases were classified as Intergroup Rhabdomyosarcoma Study (IRS) group I, 1 as group II, 8 as group III and 8 as group IV. Except for the first 5 patients, retroperitoneal node dissection was not a required staging procedure and was performed only for radiologically suspicious node metastases. Adjuvant chemotherapy was administered to all patients. Additional radiotherapy was given when nodal involvement or residual disease was documented.
Results:
The 5-year event-free survival rate was 77% for the entire series of patients, 93% for those in groups I and II, 62.5% in group III and 37.5% in group IV with a median followup of 11 years (range 2 to 20).
Conclusions:
Our report confirms the excellent prognosis of localized paratesticular rhabdomyosarcoma. Due to the accuracy of computerized tomography potential morbidity of lymphadenectomy, low rate of retroperitoneal recurrence and presumed efficacy of chemotherapy for controlling microscopic disease, retroperitoneal lymph node dissection seems unnecessary for localized disease.
